vs
Side-by-side financial comparison of Qnity Electronics, Inc. (Q) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
Qnity Electronics, Inc. is the larger business by last-quarter revenue ($1.3B vs $699.9M, roughly 1.8× QuidelOrtho Corp). Qnity Electronics, Inc. runs the higher net margin — 16.5% vs -104.7%, a 121.3% gap on every dollar of revenue. On growth, Qnity Electronics, Inc. posted the faster year-over-year revenue change (11.1% vs -3.7%). Qnity Electronics, Inc. produced more free cash flow last quarter ($568.0M vs $-94.7M).
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
Q vs QDEL — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $699.9M |
| Net Profit | $211.0M | $-733.0M |
| Gross Margin | 45.1% | — |
| Operating Margin | 21.3% | -100.7% |
| Net Margin | 16.5% | -104.7% |
| Revenue YoY | 11.1% | -3.7% |
| Net Profit YoY | 6.0% | -3583.4% |
| EPS (diluted) | $1.01 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $1.3B | $699.9M | ||
| Q2 25 | — | $613.9M | ||
| Q1 25 | — | $692.8M | ||
| Q4 24 | — | $707.8M | ||
| Q3 24 | $1.1B | $727.1M | ||
| Q2 24 | — | $637.0M | ||
| Q1 24 | — | $711.0M | ||
| Q4 23 | — | $742.6M |
| Q3 25 | $211.0M | $-733.0M | ||
| Q2 25 | — | $-255.4M | ||
| Q1 25 | — | $-12.7M | ||
| Q4 24 | — | $-178.4M | ||
| Q3 24 | $199.0M | $-19.9M | ||
| Q2 24 | — | $-147.7M | ||
| Q1 24 | — | $-1.7B | ||
| Q4 23 | — | $7.0M |
| Q3 25 | 45.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 47.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | 21.3% | -100.7% | ||
| Q2 25 | — | -29.4% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | 21.8% | 2.1% | ||
| Q2 24 | — | -18.4% | ||
| Q1 24 | — | -247.3% | ||
| Q4 23 | — | 5.4% |
| Q3 25 | 16.5% | -104.7% | ||
| Q2 25 | — | -41.6% | ||
| Q1 25 | — | -1.8% | ||
| Q4 24 | — | -25.2% | ||
| Q3 24 | 17.3% | -2.7% | ||
| Q2 24 | — | -23.2% | ||
| Q1 24 | — | -239.9% | ||
| Q4 23 | — | 0.9% |
| Q3 25 | $1.01 | $-10.78 | ||
| Q2 25 | — | $-3.77 | ||
| Q1 25 | — | $-0.19 | ||
| Q4 24 | — | $-2.54 | ||
| Q3 24 | $0.95 | $-0.30 | ||
| Q2 24 | — | $-2.20 | ||
| Q1 24 | — | $-25.50 | ||
| Q4 23 | — | $0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.0M | $98.1M |
| Total DebtLower is stronger | $1.7B | $2.5B |
| Stockholders' EquityBook value | $9.1B | $2.0B |
| Total Assets | $12.5B | $5.7B |
| Debt / EquityLower = less leverage | 0.19× | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $128.0M | $98.1M | ||
| Q2 25 | — | $151.7M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $98.3M | ||
| Q3 24 | — | $143.7M | ||
| Q2 24 | — | $107.0M | ||
| Q1 24 | — | $78.5M | ||
| Q4 23 | — | $167.3M |
| Q3 25 | $1.7B | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B | ||
| Q4 23 | — | $2.3B |
| Q3 25 | $9.1B | $2.0B | ||
| Q2 25 | — | $2.8B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | $11.1B | $3.2B | ||
| Q2 24 | — | $3.2B | ||
| Q1 24 | — | $3.3B | ||
| Q4 23 | — | $5.0B |
| Q3 25 | $12.5B | $5.7B | ||
| Q2 25 | — | $6.4B | ||
| Q1 25 | — | $6.5B | ||
| Q4 24 | — | $6.4B | ||
| Q3 24 | — | $6.8B | ||
| Q2 24 | — | $6.7B | ||
| Q1 24 | — | $6.7B | ||
| Q4 23 | — | $8.6B |
| Q3 25 | 0.19× | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.68× | ||
| Q4 23 | — | 0.45× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $782.0M | $-45.5M |
| Free Cash FlowOCF − Capex | $568.0M | $-94.7M |
| FCF MarginFCF / Revenue | 44.5% | -13.5% |
| Capex IntensityCapex / Revenue | 16.8% | 7.0% |
| Cash ConversionOCF / Net Profit | 3.71× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $782.0M | $-45.5M | ||
| Q2 25 | — | $-46.8M | ||
| Q1 25 | — | $65.6M | ||
| Q4 24 | — | $63.7M | ||
| Q3 24 | — | $117.9M | ||
| Q2 24 | — | $-97.9M | ||
| Q1 24 | — | $-700.0K | ||
| Q4 23 | — | $80.4M |
| Q3 25 | $568.0M | $-94.7M | ||
| Q2 25 | — | $-84.3M | ||
| Q1 25 | — | $9.4M | ||
| Q4 24 | — | $16.5M | ||
| Q3 24 | — | $71.4M | ||
| Q2 24 | — | $-133.2M | ||
| Q1 24 | — | $-66.8M | ||
| Q4 23 | — | $31.8M |
| Q3 25 | 44.5% | -13.5% | ||
| Q2 25 | — | -13.7% | ||
| Q1 25 | — | 1.4% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 9.8% | ||
| Q2 24 | — | -20.9% | ||
| Q1 24 | — | -9.4% | ||
| Q4 23 | — | 4.3% |
| Q3 25 | 16.8% | 7.0% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 8.1% | ||
| Q4 24 | — | 6.7% | ||
| Q3 24 | — | 6.4% | ||
| Q2 24 | — | 5.5% | ||
| Q1 24 | — | 9.3% | ||
| Q4 23 | — | 6.5% |
| Q3 25 | 3.71× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | 11.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
Q
| Semiconductor Technologies | $693.0M | 54% |
| Interconnect Solutions | $583.0M | 46% |
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
